Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Published Date: 05 Mar 2026

Adding belzutifan to standard adjuvant pembrolizumab cut the risk for recurrence or death in patients with resected clear cell renal cell carcinoma.

Read Full News

Latest News

Most NMIBC Recurrences Seen in BCG-Exposed Patients

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Study Finds Microplastics Near Tumors; Experts Doubt Results

Using LDIR, O PTIR, Py GC/MS, and SEM, researchers quantified MNPs in 191 brain samples, but experts question the unusually high particle masses and urge methodological validation.

Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

Can Exercise Extend Survival After Breast Cancer?

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

PSA Screening Overdiagnosis Rises Sharply With Age

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

High Fruit, Veggie Diet Tied to Early-Onset Lung Cancer?

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

Todays Updates

T-DXd Reduces Residual Disease in Early Breast Cancer

Neoadjuvant trastuzumab deruxtecan combination therapy reduces the residual cancer burden in high-risk early breast cancer, even if a pathologic complete response is not achieved, shows analysis.

Todays Updates

T-DXd Reduces Residual Disease in Early Breast Cancer

Neoadjuvant trastuzumab deruxtecan combination therapy reduces the residual cancer burden in high-risk early breast cancer, even if a pathologic complete response is not achieved, shows analysis.

Latest News

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Using LDIR, O PTIR, Py GC/MS, and SEM, researchers quantified MNPs in 191 brain samples, but experts question the unusually high particle masses and urge methodological validation.

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

Counterintuitive findings hint that diets rich in fruit, vegetables, and whole grains may increase the risk of lung cancer in young nonsmokers, but experts are skeptical.

News All Time

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Can Oncotype Predict Recurrence Risk in Older BC Patients?

A recent study assesses whether Oncotype DX can predict local recurrence risk in older, lower-risk patients with breast cancer who omit adjuvant radiation.

Is Vitamin D a Key to Better Breast Cancer Survival?

A prospective study links sufficient vitamin D levels at the time of breast cancer diagnosis to improved overall survival.

Where Does Mistletoe Extract Fit in Supportive Cancer Care?

Mistletoe therapy may improve the QOL of patients with cancer; however, evidence does not support a survival benefit, limiting its role in routine oncology care.

A Chemo-Free Option for Some Advanced Endometrial Cancers?

A phase 2 study suggests that immunotherapy plus radiation could spare some patients with advanced endometrial cancer from chemotherapy.

Early Tislelizumab May Boost PFS in Esophageal Cancer

For patients with locally advanced esophageal cancer, front-loading immunotherapy with induction chemo and chemoradiotherapy, without maintenance immunotherapy, may improve outcomes.

ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

Posttreatment ctDNA positivity correlates with worse relapse-free survival and earlier recurrence in patients with locally advanced cervical cancer, real-world data show.

GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer

There’s now a hint that GLP-1 receptor agonists might prevent hysterectomies in endometrial intraepithelial neoplasia/early-stage endometrial cancer, but prospective trials are needed to confirm it.

Infection Burden High With Myeloma T-Cell Therapies

A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.

Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC

A national cohort study compares the safety and efficacy of weight-based and fixed-dose pembrolizumab regimens in patients with advanced non-small cell lung cancer.

HER2 ADC Shows Promise in Recurrent Endometrial Cancer

Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

Researchers evaluate whether postoperative ctDNA-guided adjuvant atezolizumab after radical cystectomy is cost-effective compared with standard care in patients with muscle-invasive bladder cancer.

PSA Often Unchanged With Enzalutamide Progression

A stable PSA level does not rule out progression in men taking enzalutamide for advanced prostate cancer.

Assisted Dying Under Scrutiny From Medscape's Readers

Comments on a Medscape feature push past ideology to ask what evidence, oversight, and safeguards should be available for patients who choose assisted death.

Chemotherapy Boosts Survival for Older Patients With TNBC

Patients aged 70 years or older stand to benefit from adjuvant chemotherapy for triple-negative breast cancer, but the majority do not receive it.

Venetoclax Combo Shows Promise in Younger Patients With AML

Researchers conducted a systematic review and meta-analysis for studies of acute myeloid leukemia patients with a median age less than 70 treated with HMA plus venetoclax.

Recommended News For You

Six breast texture patterns linked to higher risk of invasive cancer

Dr. Prerana S. Nesargi's message for Childhood Cancer Awareness Month 2023 is to increase understanding of pediatric oncology.

BMI is linked to heart damage from chemotherapy in breast cancer patients.

ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

Fighting for others: How guilt and obligation drive desire for more intensive treatments in end-of-life cancer care

Adjuvant Belzutifan Combo Is ‘Practice Changing’ in RCC

Advanced breast cancer patients living longer thanks to improvements in treatment and care

Recommended Articles For You

The Millionaire's Battle: Does Mark Cuban Have Cancer? 

Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice 

The Different Types of Cysts and Why They Occur: Insights from a Dermatologist  

Transfusing the Future: Exploring the Possibilities of Blood Transfusions 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Risk of a second cancer after early breast cancer is low, say new findings

2.

MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information

3.

Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025

4.

Photoacoustic spectral analysis for gaining knowledge of the tumor microenvironment.

5.

Survival is extended by a new treatment option for metastatic colorectal cancer.

1.

Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence

2.

Understanding Drug-Induced Cardiotoxicity: Mechanisms, Impact, and Future Directions

3.

Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications

4.

Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies

5.

Epigenetics and Resistance: Mechanisms in Histone Methylation-Targeted Therapies

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC

2.

Navigating the Complexities of Ph Negative ALL - Part X

3.

Preventing Blood Clots: The Importance of Venous Thromboembolism Management

4.

Navigating the Complexities of Ph Negative ALL - Part VI

5.

Navigating the Complexities of Ph Negative ALL - Part XI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot